| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Khalid Mohammed Alaye. Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature. Journal of obesity. vol 2023. 2024-01-03. PMID:38169925. |
the glp-1 (glucagon-like peptide-1) hormone plays a significant role in regulating glucose metabolism and insulin secretion, and ramadan fasting can affect its production and release in the gut. |
2024-01-03 |
2024-01-06 |
Not clear |
| Tal Davidy, Iscka Yore, Tali Cukierman-Yaffe, Ramit Ravona-Springer, Abigail Livny, Orit H Lesman-Segev, Yossi Azuri, Owen Carmichael, Dimitrios Kapogiannis, Henrik Zetterberg, HungMo Lin, Mary Sano, Michal Schnaider Beer. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mechanisms of ageing and development. 2023-12-30. PMID:38159613. |
we present the rationale and design of a double-blind placebo-controlled feasibility trial combining intranasal insulin (ini) with semaglutide, a glp-1 receptor agonist, to improve cognition in older adults with metabolic syndrome (mets) and mild cognitive impairment (mci). |
2023-12-30 |
2024-01-05 |
Not clear |
| Roni Weinberg Sibony, Omri Segev, Saar Dor, Itamar Ra. Drug Therapies for Diabetes. International journal of molecular sciences. vol 24. issue 24. 2023-12-23. PMID:38138975. |
as insulin therapy remains pivotal, metformin and non-insulin agents such as glp-1 ra and sglt-2i offer compelling options. |
2023-12-23 |
2023-12-25 |
Not clear |
| Madeline Bartsch, Andreas Hahn, Shoma Berkemeye. Bridging the Gap from Enterotypes to Personalized Dietary Recommendations: A Metabolomics Perspective on Microbiome Research. Metabolites. vol 13. issue 12. 2023-12-22. PMID:38132864. |
tryptophan affects systemic hormone secretion, with indole stimulating the release of glp-1, which impacts insulin secretion, appetite suppression, and gastric emptying. |
2023-12-22 |
2023-12-24 |
human |
| Elif Beyzanur Polat, Ayse Nur Hazar-Yavuz, Ece Guler, Gul Sinemcan Ozcan, Turgut Taskin, Gokhan Duruksu, Hatice Kubra Elcioglu, Yusufhan Yazır, Muhammet Emin Ca. Sublingual Administration of Teucrium polium-Loaded Nanofibers with Ultra-Fast Release in the Treatment of Diabetes Mellitus: In Vitro and In Vivo Evaluation. Journal of pharmaceutical sciences. 2023-12-20. PMID:38123068. |
the levels of glp-1, glut-2, sglt-2, ppar-γ, insulin, and tumor necrosis factor-alpha were improved. |
2023-12-20 |
2023-12-23 |
human |
| Marc Evans, Paul Kuodi, Chisom Joyqueenet Akunna, Nicole McCreedy, Morten Donsmark, Hongye Ren, Chukwudi A Nnaj. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes & vascular disease research. vol 20. issue 6. 2023-12-19. PMID:38111352. |
cardiovascular and renal outcomes of glp-1 receptor agonists vs. dpp-4 inhibitors and basal insulin in type 2 diabetes mellitus: a systematic review and meta-analysis. |
2023-12-19 |
2023-12-21 |
Not clear |
| Marc Evans, Paul Kuodi, Chisom Joyqueenet Akunna, Nicole McCreedy, Morten Donsmark, Hongye Ren, Chukwudi A Nnaj. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes & vascular disease research. vol 20. issue 6. 2023-12-19. PMID:38111352. |
to compare the cardiovascular and renal outcomes of glp-1 ra versus dpp4i and basal insulin in the management of t2dm. |
2023-12-19 |
2023-12-21 |
Not clear |
| Gitte Rye Hinrichs, Peter Hovind, Ali Asma. The GLP-1-mediated Gut-Kidney Cross Talk in Humans: Mechanistic Insight. American journal of physiology. Cell physiology. 2023-12-18. PMID:38105752. |
these observations may potentially indicate that impaired glp-1 sensing could establish a connection between salt sensitivity and insulin resistance. |
2023-12-18 |
2023-12-21 |
human |
| Sara Elizabeth Stinson, Ierai Fernández de Retana Alzola, Emilie Damgaard Brünner Hovendal, Morten Asp Vonsild Lund, Cilius Esmann Fonvig, Louise Aas Holm, Anna Elisabet Jonsson, Christine Frithioff-Bøjsøe, Michael Christiansen, Oluf Pedersen, Lars Ängquist, Thorkild I A Sørensen, Jens Juul Holst, Bolette Hartmann, Jens-Christian Holm, Torben Hanse. Altered glucagon and GLP-1 responses to oral glucose in children and adolescents with obesity and insulin resistance. The Journal of clinical endocrinology and metabolism. 2023-12-13. PMID:38087928. |
altered glucagon and glp-1 responses to oral glucose in children and adolescents with obesity and insulin resistance. |
2023-12-13 |
2023-12-17 |
Not clear |
| Melanie Davies, Amra Ciric Alibegovic, Gayathri Anil, Uffe Christian Braae, Anders Boeck Jensen, Rikke Baastrup Nordsbor. Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. 2023-12-13. PMID:38088483. |
real-world study of the concomitant use of biphasic insulin as part 30/70 with glp-1 receptor agonist versus first-generation basal insulin with glp-1 receptor agonist in type 2 diabetes. |
2023-12-13 |
2023-12-17 |
Not clear |
| Vijaya Subramanian, Jonatan I Bagger, Vinayak Harihar, Jens J Holst, Filip K Knop, Tina Vilsbøl. An Extended Minimal Model of OGTT: Estimation of Alpha- and Beta-Cell Dysfunction, Insulin Resistance, and the Incretin Effect. American journal of physiology. Endocrinology and metabolism. 2023-12-13. PMID:38088864. |
the extended model describes glucose and hormone dynamics in ogtt including the contribution of the incretins, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), to insulin secretion. |
2023-12-13 |
2023-12-17 |
human |
| Melody A de Laat, Danielle M Fitzgerald, Patricia A Harris, Simon R Baile. A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies1. Journal of animal science. 2023-12-09. PMID:38066683. |
glucagon-like peptide-1 (glp-1), an incretin hormone released from the gastrointestinal tract, enhances insulin release, and is increased post-prandially in ponies with id. |
2023-12-09 |
2023-12-17 |
Not clear |
| Melody A de Laat, Danielle M Fitzgerald, Patricia A Harris, Simon R Baile. A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies1. Journal of animal science. 2023-12-09. PMID:38066683. |
the aim of this study was to determine whether blocking the glp-1 receptor reduces the insulin response to a high glycaemic meal. |
2023-12-09 |
2023-12-17 |
Not clear |
| Melody A de Laat, Danielle M Fitzgerald, Patricia A Harris, Simon R Baile. A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies1. Journal of animal science. 2023-12-09. PMID:38066683. |
blood samples were taken before feeding and peptide administration, and then at 30 min intervals via a jugular catheter for 6 hours for the measurement of insulin, glucose and active glp-1. |
2023-12-09 |
2023-12-17 |
Not clear |
| Melody A de Laat, Danielle M Fitzgerald, Patricia A Harris, Simon R Baile. A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies1. Journal of animal science. 2023-12-09. PMID:38066683. |
the lower overall insulin response to the maize meal after treatment with the antagonist demonstrates that blocking the glp-1 receptor partially reduced insulin production in response to a high starch, high glycaemic index, diet. |
2023-12-09 |
2023-12-17 |
Not clear |
| Melody A de Laat, Danielle M Fitzgerald, Patricia A Harris, Simon R Baile. A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycaemic meal in ponies1. Journal of animal science. 2023-12-09. PMID:38066683. |
using a different methodological approach to published studies, this study also confirmed that glp-1 does contribute to the excessive insulin production in ponies with id. |
2023-12-09 |
2023-12-17 |
Not clear |
| Qianfeng Xiong, Jing Wang, Kewen Huang, Wenbo Li, Lihui Zhan. Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease. Frontiers in bioscience (Landmark edition). vol 28. issue 11. 2023-12-08. PMID:38062835. |
glucagon-like peptide-1 (glp-1), an incretin hormone primarily secreted by intestinal l cells, regulates glucose metabolism by increasing insulin synthesis and secretion, decreasing plasma glucagon levels, reducing food intake, and slowing gastric emptying. |
2023-12-08 |
2023-12-17 |
Not clear |
| Qilong Zhang, Jianping Ye, Xiaohui Wan. Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development. Experimental biology and medicine (Maywood, N.J.). 2023-12-07. PMID:38058030. |
glucagon-like peptide-1 (glp-1), secreted by intestinal l-cells, plays a pivotal role in the modulation of β-cell insulin secretion in a glucose-dependent manner, concurrently promoting β-cell survival and β-cell mass. |
2023-12-07 |
2023-12-10 |
Not clear |
| Rohani, Ellin Febrina, Indah Suasani Wahyuni, Jutti Levit. Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV. Drug design, development and therapy. vol 17. 2023-12-01. PMID:38024536. |
this, in turn, leads to an extension of glp-1's duration of action, prolongs gastric emptying, enhances insulin sensitivity, and ultimately results in the reduction of blood glucose levels. |
2023-12-01 |
2023-12-07 |
human |
| Rikke Viggers, Nicklas Højgaard-Hessellund Rasmussen, Peter Vestergaar. Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review. JBMR plus. vol 7. issue 11. 2023-12-01. PMID:38025038. |
the group of hormones known as incretins, which includes gastric inhibitory peptide (gip) and glucagon-like peptide 1 (glp-1), play a role in regulating bowel function and insulin secretion during feeding. |
2023-12-01 |
2023-12-07 |
human |